Attovia Therapeutics, Inc.
NASDAQ · ATTO·San Carlos, CA·Small-cap·Phase 1
Clinical-stage developer of ATTOBODY biologics for immune-mediated diseases. Lead IL-31 antagonist ATTO-1310 is in Phase 1 development for chronic itch and atopic dermatitis; additional bispecific and trispecific programs target skin disease and inflammatory bowel disease.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Attovia Corporate Presentation | Corporate overview | September 1, 2026 | 28 | Source |